Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 408.18 USD 0.72% Market Closed
Market Cap: 105.1B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Vertex Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vertex Pharmaceuticals Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Revenue
$2.1B
CAGR 3-Years
41%
CAGR 5-Years
65%
CAGR 10-Years
50%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Vertex Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Vertex Pharmaceuticals Inc

Not Available

Breakdown by Segments
Vertex Pharmaceuticals Inc

Total Revenue: 9.9B USD
100%
Product Revenues, Net: 9.9B USD
100%
Trikafta/Kaftrio: 8.9B USD
90.6%
Kalydeco: 475.5m USD
4.8%
Orkambi: 326m USD
3.3%
Symdeko/Symkevi: 123m USD
1.2%
Show More
Show Less

Vertex Pharmaceuticals Inc
Glance View

Market Cap
105.2B USD
Industry
Biotechnology
Economic Moat
Narrow

In the bustling landscape of biotechnology, Vertex Pharmaceuticals Inc. stands out as a dynamic powerhouse that has deftly carved a niche in the complex domain of genetic therapies. Founded in 1989, the company initially embarked on a mission to revolutionize drug discovery through a cutting-edge rational drug design approach. Armed with an innovative spirit and a focus on niche markets, Vertex turned its attention towards cystic fibrosis—a life-shortening genetic disorder affecting the lungs and digestive system. The company’s breakthrough came with the development and approval of the first therapies that address the underlying cause of cystic fibrosis, rather than just alleviating symptoms. These products, including Kalydeco and Trikafta, have repositioned Vertex from a scrappy biotech upstart to a dominating force in the drug market as these life-changing treatments not only improve patient outcomes but also command premium pricing. Vertex’s business model brilliantly capitalizes on its deep investment in research and development, allowing it to maintain a robust pipeline that promises ongoing growth. By channeling a substantial portion of its revenue back into R&D, Vertex seeks to extend its therapeutic successes beyond cystic fibrosis into other serious diseases with high unmet needs, such as sickle cell disease and beta-thalassemia. This strategic reinvestment supports a cyclical framework of innovation—capitalize on current successes while laying down the groundwork for future therapies. With a singular focus on specialty drugs that target specific genetic mutations or pathways, Vertex not only thrives on the immediate financial returns of its blockbuster drugs but continually invests in scientifically ambitious endeavors, thus reinforcing its status as a leader in the precision medicine sector.

VRTX Intrinsic Value
261.44 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Vertex Pharmaceuticals Inc's Revenue?
Revenue
10.6B USD

Based on the financial report for Sep 30, 2024, Vertex Pharmaceuticals Inc's Revenue amounts to 10.6B USD.

What is Vertex Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
30%

Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for Vertex Pharmaceuticals Inc have been 14% over the past three years , 24% over the past five years , and 30% over the past ten years .

Back to Top